Bruno Montanari

Bruno Montanari is a Partner at Seroba, a European life sciences venture capital firm headquartered in Dublin with offices in Paris and Milan. He joined the firm in late 2017 and works from the Paris office as part of Seroba's cross-border investment team. His career spans more than two decades in healthcare venture capital and investment banking, with a consistent focus on the pharmaceutical, biotechnology, and medical device industries.

Before Seroba, Bruno was a Partner at Omnes Capital in Paris, where he led life sciences investments for the venture capital team. His earlier venture experience includes roles at Atlas Venture (Paris/London) and CDP Capital (Paris/Montreal). He began his career in 1999 in London, working in the healthcare teams of the investment banking divisions of Deutsche Bank and, subsequently, Merrill Lynch.

On the education side, Bruno graduated in 1998 with a PharmD from the Université René Descartes (Paris V) and, in the same year, completed a Master's degree in Strategic Management at HEC Paris. This combination of scientific training and finance underpins his work on the boards of Seroba portfolio companies and his role in the firm's therapeutics and medtech investing.

Bruno was one of the partners representing Seroba around the 2024 final close of Seroba Fund IV, which closed above target at €123M ($134M). He is a recurring participant on the European life sciences conference circuit, appearing as a speaker at events such as IPEM Cannes 2024 and Phacilitate.

• Invests at seed and Series A, writing checks roughly in the $100K–$5M range into early-stage life sciences companies.
• Sector focus on biotechnology / therapeutics, medical devices, diagnostics, and consumer health — the core of Seroba's biotech-and-medtech mandate.
• Backs companies through Seroba's stated strategy of "value creation through backing winning innovations in biotech and medtech," typically taking a board seat and an active hands-on role.
• Seroba Fund IV targets up to ~12 investments, implying a concentrated, high-conviction portfolio approach rather than spray-and-pray.
• On closing Fund IV, Bruno noted the firm was "extremely pleased to complete a successful fundraising above our initial target, in what remains a challenging environment" — signaling disciplined capital deployment in a tight biotech funding market.